UnknownNot Applicable

Management of Non Convulsive Status Epilepticus

Egypt100 participantsStarted 2017-12

Plain-language summary

Non convulsive status epilepticus is a persistent change in behavioural and or mental process from baseline associated with continuous epileptiform activity in electroencephalograph,it occur in about 50 percent in patients with coma and convulsions and in 8-13 percent in intensive care unit patients

Who can participate

Age range

12 Months – 18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * patients who have generalized tonic colonic convulsions and prolonged post ictal state more than 30 minutes * patients presented with un explained psychic or speech disorder * patients presented with stupor or confusion * Patients presented with un explained coma Exclusion Criteria: * patients with progressive neurological disease * Patients with severe cerebral anoxia * Patients with liver or hepatic impairment

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Number of cured patients

Timeframe: An average of 1 year

Trial details

NCT IDNCT03245099

SponsorAssiut University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2018-12

Contact for this trial

Gamal Askar, MD

01111686162 Gamal.askar@med.au.edu.eg

View on ClinicalTrials.gov More Status Epilepticus trials